Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies-Reference-Cited by-同舟云学术

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

Published:2024-03 Issue: Volume:200 Page:113587
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Parisi Alessandro^ORCID,Delaunay Blandine,Pinterpe Giada^ORCID,Hollebecque Antoine^ORCID,Blanc Jean Frederic,Bouattour Mohamed^ORCID,Assenat Eric,Ben Abdelghani Meher^ORCID,Sarabi Matthieu,Niger Monica,Vivaldi Caterina^ORCID,Mandalà Mario^ORCID,Palloni Andrea^ORCID,Bensi Maria,Garattini Silvio Ken,Tougeron David^ORCID,Combe Pierre,Salati Massimiliano,Rimini Margherita,Cella Chiara Alessandra,Tucci Marco,Diana Anna^ORCID,Mori Elena,Longarini Raffaella,Artru Pascal^ORCID,Roth Gael^ORCID,Evesque Ludovic,Vienne Agathe,Turpin Anthony^ORCID,Hiret Sandrine,Bourgeois Vincent,Herve Camille,Paulon Rodolphe^ORCID,Stacoffe Marion,Malka David^ORCID,Neuzillet Cindy^ORCID,Edeline Julien^ORCID,Lievre Astrid,Guimbaud Rosine^ORCID,Chapda Marie Christelle Pajiep,Rimassa Lorenza^ORCID,Giampieri Riccardo,Valle Juan^ORCID,Berardi Rossana,Fares Nadim

Publisher

Elsevier BV

Reference29 articles.

1. ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Vogel;Ann Oncol,2023

2. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5;Lepage;Eur J Cancer,2015

3. ABC-02 Trial Investigators. cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

4. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1;Oh;NEJM Evid,2022

5. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial;Kelley;Lancet 3 juin,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10

2. Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2);ESMO Real World Data and Digital Oncology;2024-09

3. Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features;Digestive and Liver Disease;2024-05